Nineteen relapsing remitting ( RR ) MS patients , randomly assigned to undergo either NTZ ( n = @ ) or IFN B @B ( n = @ ) treatment , who had previously received NTZ for at least @ months with disease stability and fearing or at risk for PML were included .